When should albumin be administered after a large‑volume thoracentesis (≥1.5 L) in patients such as the elderly, those with cirrhosis, nephrotic syndrome, severe hypoalbuminemia, or hemodynamic instability?

Albumin Replacement After Thoracentesis in Cirrhosis

Albumin should be administered after large-volume thoracentesis (≥1.5 L) in patients with hepatic hydrothorax at a dose of 6–8 g per liter of pleural fluid removed, with particular consideration for albumin replacement even at lower volumes in patients with hypotension, renal insufficiency, or electrolyte abnormalities. 1

Volume Thresholds for Albumin Administration

For thoracentesis volumes ≥1.5 L, albumin replacement is recommended to prevent post-procedural circulatory dysfunction, following the same pathophysiologic principles as large-volume paracentesis. 1

• The 2025 AGA Clinical Practice Update explicitly recommends albumin when >5 L of ascites is removed during paracentesis, with consideration for smaller volumes in high-risk patients. 1
• While specific thoracentesis volume thresholds are less rigorously studied than paracentesis, the same circulatory dysfunction mechanisms apply when large volumes of transudative pleural fluid are removed in cirrhotic patients. 2
• Patients with hypotension, renal insufficiency (creatinine >1.0 mg/dL), or electrolyte abnormalities should receive albumin even for removal of smaller volumes (<5 L). 1

Dosing Recommendations

The standard dose is 6–8 g of 20%–25% intravenous albumin per liter of pleural fluid removed. 1, 3

• For a 2 L thoracentesis: administer 12–16 g of albumin 3
• For a 3 L thoracentesis: administer 18–24 g of albumin 3
• For volumes >5 L: administer 30–40 g or more of albumin 3
• Albumin should be infused slowly at the end of the procedure to avoid cardiac overload in patients with latent cirrhotic cardiomyopathy. 4, 3

High-Risk Populations Requiring Lower Thresholds

Several patient populations warrant albumin replacement at lower volume thresholds:

Elderly Patients

• Age-related decreased cardiovascular reserve increases susceptibility to circulatory dysfunction after fluid removal. 1
• Consider albumin for volumes ≥1.5 L in elderly patients with cirrhosis and hepatic hydrothorax. 1

Cirrhosis with Complications

• Patients with baseline renal dysfunction (creatinine >1.0 mg/dL or BUN >30 mg/dL) benefit most from albumin administration. 2
• Those with severe hepatic decompensation (bilirubin >5 mg/dL) have higher risk of post-procedural complications. 2
• Cirrhotic patients are at risk for hepatorenal syndrome, which albumin helps prevent. 5, 2

Nephrotic Syndrome

• Severe proteinuria and hypoalbuminemia create baseline oncotic deficits. 6
• These patients rapidly lose infused albumin through urinary excretion, making albumin less effective for chronic management but still beneficial acutely for circulatory support. 6

Severe Hypoalbuminemia

• Baseline serum albumin <2.5 g/dL significantly increases risk of post-procedural circulatory dysfunction. 4, 3
• Hypoalbuminemia impairs drug binding and increases free drug concentrations, complicating management. 7

Hemodynamic Instability

• Any patient with pre-existing hypotension or signs of shock should receive albumin regardless of volume removed. 1, 6
• Albumin is hyperoncotic and expands plasma volume by 3–4 times the volume administered. 6

Pathophysiology and Clinical Benefits

The removal of large volumes of fluid triggers post-procedural circulatory dysfunction through several mechanisms:

• Removal of >5 L markedly reduces effective blood volume, activating vasoconstrictor systems (renin-angiotensin-aldosterone, sympathetic nervous system). 3
• Approximately 20% of patients develop hepatorenal syndrome or dilutional hyponatremia after large-volume removal without albumin. 3
• Vasoconstriction increases intrahepatic resistance, raising portal pressure and promoting fluid re-accumulation. 3
• Meta-analysis demonstrates albumin reduces post-paracentesis circulatory dysfunction by 61% (OR 0.39,95% CI 0.27–0.55). 3
• Mortality is reduced by 36% with albumin compared to alternative plasma expanders (OR 0.64,95% CI 0.41–0.98). 3
• Hyponatremia risk decreases by 42% (OR 0.58,95% CI 0.39–0.87). 3

Hepatic Hydrothorax-Specific Considerations

Patients with hepatic hydrothorax requiring therapeutic thoracentesis should undergo the procedure for both symptom relief and lung expansion. 1

• Hepatic hydrothorax represents transudative pleural effusion in cirrhosis, confirmed by pleural fluid-to-serum albumin gradient ≥1.1. 2, 8
• For liver transplant consideration, documentation should include thoracentesis >1 L weekly for 4 weeks with transudative characteristics. 2
• The same circulatory dysfunction mechanisms that occur with paracentesis apply to thoracentesis in these patients. 2, 1

Alternative Plasma Expanders: Not Recommended

Alternative plasma expanders are inferior to albumin for large-volume procedures and should not be used. 4, 3

• Dextran-70 and polygeline show comparable efficacy only when <5 L are removed. 4, 3
• When >5 L are removed, albumin is definitively superior. 4, 3
• Polygeline carries prion transmission risk and is discontinued in many countries. 4, 3
• Starch-based expanders are associated with renal failure and hepatic accumulation. 4, 3
• Saline alone does not prevent circulatory dysfunction and is inadequate. 4

Cost-Effectiveness

Despite higher upfront costs, albumin is more cost-effective than cheaper alternatives by reducing liver-related complications within 30 days post-procedure. 4, 3

Common Pitfalls and Caveats

• Avoid fluid overload: Infuse albumin slowly, particularly in patients with latent cirrhotic cardiomyopathy or baseline fluid overload. 4, 3
• Do not use albumin for chronic hypoalbuminemia or nutritional support in nephrotic syndrome or chronic liver disease—it is rapidly excreted or metabolized without addressing underlying pathology. 6, 9
• Monitor for volume overload: Doses exceeding 87.5 g in spontaneous bacterial peritonitis have been associated with worse outcomes, possibly from fluid overload. 10
• Ensure adequate hydration: If the patient is dehydrated, additional crystalloids must be given, or 5% albumin should be used instead of 25% albumin. 6
• Therapeutic drug monitoring may be necessary in patients with severe hypoalbuminemia receiving medications with high protein binding. 7